NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2022
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Generated Record Orders for Over 105 Spatial Biology Instruments in Q4, Representing
Q4 Product and Service Revenue of Over
“NanoString continued to build on our strong spatial biology franchise in 2022, capturing a record 105+ new system orders in the fourth quarter, bringing growth in spatial biology system orders to
Q4 and 2022 Highlights
Spatial Biology
-
Secured customer orders for more than 105 spatial biology systems in Q4, including approximately 80 for CosMx™ Spatial Molecular Imagers (SMI) and over 25 for GeoMx Digital Spatial Profilers (DSP), an increase of
50% as compared to 2021 for both the fourth quarter and full year 2022
-
CosMx SMI highlighted on the cover of the
December 2022 issue of Nature Biotechnology, demonstrating high-resolution, single cell imaging of RNA and protein
-
CosMx SMI featured in the
January 2023 issue ofNational Geographic . Researchers atWake Forest used CosMx to perform high-resolution imaging of brain tissue in their ongoing Alzheimer’s research. They were able to discover rare senescence cells that contribute to neurodegeneration
-
Total peer-reviewed publications featuring our spatial biology platforms were approximately 195 as of
December 2022 , representing an increase of approximately 105 publications in the last 12 months
-
NanoString was named the Gold Sponsor for 2023 Advances in Genome Biology and Technology (AGBT) meeting, where we will host a workshop onFebruary 7, 2023 highlighting advances in our spatial biology platforms and showcasing research conducted by our collaborators and customers
nCounter
-
Concluded 2022 with an nCounter installed base of approximately 1,120 systems, an increase of approximately
7% as compared to 2021
-
Total peer-reviewed publications featuring nCounter were approximately 6,520 as of
December 2022 , representing an increase of approximately 1,320 publications in the last 12 months
Preliminary Financial Results
-
For the fourth quarter of 2022, product and service revenue is expected to be over
, within our guidance range of$34 million to$33 $35 million
-
For the full year 2022, product and service revenue is expected to be approximately
, within our guidance range of$127 million to$125 $127 million
-
As of
December 31, 2022 , cash, cash equivalents and short-term investments is expected to total more than$195 million
These preliminary results are based on management's initial analysis of operations for the quarter and year ended
About
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our preliminary estimates of fourth quarter and fiscal year 2022 operating results and financial condition, expectations for demand for our products and growth in our business, the impact of new products and expansion into new markets, and the growth trajectory of our nCounter and spatial biology franchises. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include the risk that our actual financial results for the three months and year ended
The
View source version on businesswire.com: https://www.businesswire.com/news/home/20230108005034/en/
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768
Source: